Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

81. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)

Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials) 29472008 2018 02 23 1879-1913 2018 Feb 02 The American journal of cardiology Am. J. Cardiol. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials (...) ). S0002-9149(18)30093-6 10.1016/j.amjcard.2017.12.040 Patients with previous atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) are at high risk of future cardiovascular events. Despite maximally tolerated doses of statins, many patients still have elevated low-density lipoprotein cholesterol (LDL-C) levels. We evaluated the efficacy and safety of alirocumab in patients with ASCVD and/or HeFH on a maximally tolerated dose of statin (rosuvastatin 20

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

82. Predicting new‐onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study

Predicting new‐onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study Predicting new-onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study Nasrien E. Ibrahim 1 , Asya Lyass 2,3 , Hanna K. Gaggin 1,2 ,Yuyin Liu 2 , Roland R.J. van Kimmenade 4,5 , Shweta R. Motiwala 6 , Noreen P (...) ; risk strati?cation in- creased the incremental value per biomarker to predict new- onset HF,especiallyin patients withHFwithreduced ejection fraction. 20 In another study by Wannamethee and colleagues of 3870 men aged 60–79 years not diagnosed with HF, NT- proBNP was associated with HF in those with and without established cardiovascular disease. 21 Such ?ndings illustrate that perhaps biomarkers would improve discrimination, cali- bration,andportabilityofnew-onsetHFriskpredictionscores. We found

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

83. Effect of Obstructive Sleep Apnea Treatment on Renal Function in Patients with Cardiovascular Disease

Effect of Obstructive Sleep Apnea Treatment on Renal Function in Patients with Cardiovascular Disease 28743190 2017 12 11 2018 01 24 1535-4970 196 11 2017 Dec 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Effect of Obstructive Sleep Apnea Treatment on Renal Function in Patients with Cardiovascular Disease. 1456-1462 10.1164/rccm.201703-0603OC Obstructive sleep apnea (OSA) is associated with impaired renal function, but uncertainty exists over (...) whether OSA treatment can influence renal outcomes. To determine the effects of continuous positive airway pressure (CPAP) on renal function in subjects with coexisting OSA and cardiovascular disease. This was a substudy of the international SAVE (Sleep Apnea Cardiovascular Endpoints) trial, in which 2,717 patients with moderate to severe OSA and established coronary or cerebrovascular disease were randomized to receive either CPAP plus usual care or usual care alone. Renal function and adverse renal

EvidenceUpdates2018

84. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease 28904068 2018 02 07 1524-4539 137 2 2018 Jan 09 Circulation Circulation Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. 119-129 10.1161/CIRCULATIONAHA.117.028268 Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity (...) and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We investigated the effects of empagliflozin on clinical outcomes in patients with type 2 diabetes mellitus, established

EvidenceUpdates2018

85. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study

Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study 29297057 2018 02 06 2168-6114 178 2 2018 Feb 01 JAMA internal medicine JAMA Intern Med Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study. 229-238 10.1001/jamainternmed.2017.7720 The associations between cardiovascular disease (...) (CVD) and inhaled long-acting β2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic obstructive pulmonary disease (COPD) are greatly debated. Pivotal and relevant randomized clinical trials included prior LABA or LAMA users and excluded patients with baseline CVD; therefore, cardiovascular events arising from first-time LABA or LAMA use, if any, could not be observed. There is an urgent need to examine whether new use of and duration since initiating LABAs and LAMAs could

EvidenceUpdates2018

86. Radiation-Induced Cardiovascular Disease: Mechanisms and Importance of Linear Energy Transfer

Radiation-Induced Cardiovascular Disease: Mechanisms and Importance of Linear Energy Transfer January 2018 | Volume 5 | Article 5 1 Review published: 31 January 2018 doi: 10.3389/fcvm.2018.00005 Frontiers in Cardiovascular Medicine | www.frontiersin.org Edited by: Magnus Bäck, Karolinska Institute (KI), Sweden Reviewed by: Cécile Oury, University of Liège, Belgium Christoph Eugen Hagemeyer, Monash University, Australia *Correspondence: K. Jane Grande-Allen grande@rice.edu Specialty section (...) : This article was submitted to Atherosclerosis and Vascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine Received: 31 October 2017 Accepted: 09 January 2018 Published: 31 January 2018 Citation: Sylvester CB, Abe J-i, Patel ZS and Grande-Allen KJ (2018) Radiation- Induced Cardiovascular Disease: Mechanisms and Importance of Linear Energy Transfer. Front. Cardiovasc. Med. 5:5. doi: 10.3389/fcvm.2018.00005 Radiation-induced Cardiovascular Disease: Mechanisms and importance of Linear

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro

87. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study.

Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. OBJECTIVE: To examine the risks of myocardial infarction, stroke (ischaemic and haemorrhagic), peripheral artery disease, venous thromboembolism, atrial fibrillation or atrial flutter, and heart failure in patients with migraine and in a general population comparison cohort. DESIGN: Nationwide, population based cohort study. SETTING: All Danish hospitals and hospital outpatient clinics from 1995 to 2013 (...) . In a subcohort of patients, the associations persisted after additional multivariable adjustment for body mass index and smoking. CONCLUSIONS: Migraine was associated with increased risks of myocardial infarction, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, and atrial fibrillation or atrial flutter. Migraine may be an important risk factor for most cardiovascular diseases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence

BMJ2018 Full Text: Link to full Text with Trip Pro

88. Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease

Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease Frontiers | Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease | Cardiovascular Medicine Toggle navigation Login using You can login by using one of your existing accounts. We will be provided with an authorization token (please note: passwords are not shared with us) and will sync your accounts for you. This means that you will not need (...) ' affiliations are the latest provided on their Loop research profiles and may not reflect their situation at the time of review. TABLE OF CONTENTS Supplementary Material total views SHARE ON Review ARTICLE Front. Cardiovasc. Med., 05 January 2018 | Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease 1 , 2 and 3 * 1 Boston University School of Public Health, Boston, MA, United States 2 Department of Surgery, Introduction to Clinical and Surgical Techniques

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro

89. Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? ORIGINAL RESEARCH ARTICLE Diagnoses of Cardiovascular Disease or Substance Addiction/ Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Kathleen A. Fairman 1 • Lindsay E. Davis 1 • Alyssa M. Peckham 1 • David A. Sclar 1 Published online: 5 January 2018 The Author(s) 2018 (...) . This article is an open access publication Abstract Background Among US adults, utilization of pharma- cotherapy for attention-de?cit hyperactivity disorder (ADHD) has increased more than ninefold since 1995–1996. Potential contraindications to ADHD phar- macotherapy include serious cardiovascular disease (CVD) and, for stimulants, addictions and bipolar disorder (BPD). Objective To assess the prevalence of potential con- traindications among adults treated with ADHD pharmacotherapy. Methods A

Drugs - real world outcomes2018 Full Text: Link to full Text with Trip Pro

90. Community Guide Cardiovascular Disease Economic Reviews: Tailoring Methods to Ensure Utility of Findings

Community Guide Cardiovascular Disease Economic Reviews: Tailoring Methods to Ensure Utility of Findings 29153116 2017 11 20 1873-2607 53 6S2 2017 Dec American journal of preventive medicine Am J Prev Med Community Guide Cardiovascular Disease Economic Reviews: Tailoring Methods to Ensure Utility of Findings. S155-S163 S0749-3797(17)30322-7 10.1016/j.amepre.2017.06.012 The Community Preventive Services Task Force recommended five interventions for cardiovascular disease prevention between 2012 (...) systematic economic reviews of public health interventions to respond to challenges with the synthesis of evidence and provide useful findings for public health decision makers. Published by Elsevier Inc. Chattopadhyay Sajal K SK Community Guide Branch, Division of Public Health Information Dissemination, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: skc9@cdc.gov. Jacob Verughese V Community Guide Branch

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

91. Dietary patterns and cardiovascular disease outcomes

Dietary patterns and cardiovascular disease outcomes An Evidence Check rapid review brokered by the Sax Institute for the National Heart Foundation of Australia. April 2017. Dietary Patterns and Cardiovascular Disease Outcomes An Evidence Check rapid review brokered by the Sax Institute for the National Heart Foundation of Australia. April 2017. This report was prepared by: Clare Collins, Tracy Burrows, Megan Rollo. University of Newcastle April 2017 © Sax Institute 2017 This work is copyright (...) Citation: Collins C, Burrows T, Rollo M. Dietary Patterns and Cardiovascular Disease Outcomes: an Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the National Heart Foundation of Australia, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily a comprehensive review of all literature relating to the topic area. It was current at the time

Sax Institute Evidence Check2018

92. Dietary fats and cardiovascular disease

Dietary fats and cardiovascular disease Dietary fats and cardiovascular disease An Evidence Check rapid review brokered by the Sax Institute for the National Heart Foundation. September 2017 2 DIETARY FATS AND CARDIOVASCULAR DISEASE OUTCOMES | SAX INSTITUTE An Evidence Check rapid review brokered by the Sax Institute for the National Heart Foundation. March 2017. This report was prepared by: Professor Peter Clifton and Dr Jennifer Keogh University of South Australia September 2017 © Sax (...) @saxinstitute.org.au Phone: +61 2 9188 9500 Suggested Citation: Clifton P and Keogh J. Dietary fats and cardiovascular disease: an Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the National Heart Foundation of Australia, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily a comprehensive review of all literature relating to the topic area

Sax Institute Evidence Check2018

93. Primary prevention of cardiovascular disease

Primary prevention of cardiovascular disease Prescrire IN ENGLISH - Spotlight ''In the January issue of Prescrire International: Primary prevention of cardiovascular disease '', 1 January 2018 {1} {1} {1} | | > > > In the January issue of Prescrire International: Primary prevention of cardiovascular disease Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  (...) Spotlight In the January issue of Prescrire International: Primary prevention of cardiovascular disease FREE DOWNLOAD This month's sample page from the Reviews section makes the point that statins and hypotensive drugs ought not necessarily to be prescribed for everyone who may be at risk. Full text available for free download. Summary In a large-scale placebo-controlled tria l, about 13 000 patients at risk of a first cardiovascular event were followed for approximately six years. Low-dose rosuvastatin

Prescrire2018

94. Diabetic cardiovascular disease

Diabetic cardiovascular disease Diabetic cardiovascular disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Diabetic cardiovascular disease Last reviewed: August 2018 Last updated: March 2018 Summary Cardiovascular disease (CVD) and stroke account for about two-thirds of deaths in people with diabetes. People with diabetes have a 2- to 4-fold increased risk of CVD and are up to 3 times more likely to die after MI (...) ://care.diabetesjournals.org/content/41/Supplement_1 http://www.ncbi.nlm.nih.gov/pubmed/29222372?tool=bestpractice.com Diabetes is an established major risk factor for the development of cardiovascular disease, including coronary artery disease (CAD), cerebrovascular disease (stroke or transient ischaemic attack [TIA]), and peripheral arterial disease. This monograph will discuss CAD in greatest detail. History and exam presence of risk factors chest pain dyspnoea on exertion hypotension rales S3 gallop BP >140/90 mmHg

BMJ Best Practice2018

95. Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols

Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols WHO IRIS: Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols Browse Related links Files in This Item: File Description Size Format 1.7 MB Adobe PDF Title: Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols Authors: Issue Date: 2018 Publisher: World Health

WHO2018

96. Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling

Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling WHO IRIS: Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling Browse Related links Files in This Item: File Description Size Format 2.21 MB Adobe PDF Title: Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling Authors: Issue Date: 2018 Publisher: World Health Organization

WHO2018

97. Technical package for cardiovascular disease management in primary health care: systems for monitoring

Technical package for cardiovascular disease management in primary health care: systems for monitoring WHO IRIS: Technical package for cardiovascular disease management in primary health care: systems for monitoring Browse Related links Files in This Item: File Description Size Format 899.76 kB Adobe PDF Title: Technical package for cardiovascular disease management in primary health care: systems for monitoring Authors: Issue Date: 2018 Publisher: World Health Organization Place of publication

WHO2018

98. Technical package for cardiovascular disease management in primary health care: team-based care

Technical package for cardiovascular disease management in primary health care: team-based care WHO IRIS: Technical package for cardiovascular disease management in primary health care: team-based care Browse Related links Files in This Item: File Description Size Format 941.62 kB Adobe PDF Title: Technical package for cardiovascular disease management in primary health care: team-based care Authors: Issue Date: 2018 Publisher: World Health Organization Place of publication: Geneva Language

WHO2018

99. Predicting effective factors on eating behaviors in the prevention of cardiovascular disease based on the PRECEDE model

Predicting effective factors on eating behaviors in the prevention of cardiovascular disease based on the PRECEDE model Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir December 2017, Volume: 9, Issue: 12, Pages: 5894-5901, DOI: http://dx.doi.org/10.19082/5894 Corresponding author: Assistant Professor Dr. Mohabbat Mohseni, Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. Tel (...) cited, the use is non-commercial and no modifications or adaptations are made. Page 5894 Predicting effective factors on eating behaviors in the prevention of cardiovascular disease based on the PRECEDE model Samera Radmerikhi 1 , Seyed Vahid Ahmady Tabatabaei 2 , Yunes Jahani 3 , Mohabbat Mohseni 4 1 MSc. of Health Education, Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran 2 M.D-MPH-Ph.D., Assistant

Electronic physician2017 Full Text: Link to full Text with Trip Pro

100. Anti-inflammatory Nanomedicine for Cardiovascular Disease

Anti-inflammatory Nanomedicine for Cardiovascular Disease December 2017 | Volume 4 | Article 87 1 Review published: 22 December 2017 doi: 10.3389/fcvm.2017.00087 Frontiers in Cardiovascular Medicine | www.frontiersin.org Edited by: Ichiro Manabe, Chiba University, Japan Reviewed by: Vasilios Gabriel Athyros, Aristotle University of Thessaloniki, Greece Xiao-feng Yang, Temple University, United States *Correspondence: Tetsuya Matoba matoba@cardiol.med. kyushu-u.ac.jp Specialty section (...) : This article was submitted to Atherosclerosis and Vascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine Received: 21 September 2017 Accepted: 12 December 2017 Published: 22 December 2017 Citation: Katsuki S, Matoba T, Koga J, Nakano K and Egashira K (2017) Anti-inflammatory Nanomedicine for Cardiovascular Disease. Front. Cardiovasc. Med. 4:87. doi: 10.3389/fcvm.2017.00087 Anti-inflammatory Nanomedicine for Cardiovascular Disease Shunsuke Katsuki 1,2 , Tetsuya Matoba 1 *, Jun

Frontiers in cardiovascular medicine2017 Full Text: Link to full Text with Trip Pro